Preliminary outcomes of neoadjuvant chemoimmunotherapy combined with transoral robotic surgery for locally advanced oropharyngeal squamous cell carcinoma
10.3760/cma.j.cn115330-20231205-00273
- VernacularTitle:新辅助化学免疫治疗联合经口机器人手术治疗局部晚期口咽鳞癌的初步疗效
- Author:
Renhui CHEN
1
;
Faya LIANG
;
Ping HAN
;
Peiliang LIN
;
Xijun LIN
;
Jingyi WANG
;
Xiangwei KONG
;
Xiaoming HUANG
Author Information
1. 中山大学孙逸仙纪念医院耳鼻咽喉头颈外科，广州 510280
- Keywords:
Oropharyngeal neoplasms;
Carcinoma, squamous cell;
Transoral robotic surgery;
Neoadjuvant therapy;
Chemotherapy;
Immunotherapy
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2024;59(4):329-334
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of neoadjuvant chemoimmunotherapy (NACI) combined with transoral robotic surgery (TORS) in the treatment of locally advanced oropharyngeal squamous cell carcinoma (OPSCC).Methods:This was a retrospective study of 15 patients with locally advanced OPSCC who underwent TORS after neoadjuvant therapy (NAT) at the Department of Otolaryngology-Head and Neck Surgery of Sun Yat-sen Memorial Hospital of Sun Yat-sen University from April 2019 to February 2023. There were 12 males and 3 females, aged 31 to 74 years. Twelve cases were tonsil cancer, and 3 cases were tongue base cancer. There were 11 cases in stage Ⅲ and 4 cases in stage Ⅳ. Two patients received neoadjuvant chemotherapy and 13 patients received NACI, with 2 to 3 cycles, and all patients underwent TORS after multidisciplinary team consultation. The clinicopathological characteristics, surgical outcomes, and oncological results were summarized.Results:All surgeries were successfully completed with negative surgical margins, and no case was required conversion surgery. All patients were fed via nasogastric tubes postoperatively, with a median gastric tube stay of 7 days (range: 2-60 days). No tracheotomy was applied. There were no major complications such as postoperative bleeding. Pathological complete response (pCR) was found in 10 cases (76.9%) among the 13 patients with NACI. The follow-up time was 21 months (range: 10-47 months), and there was no death or distant metastasis. One patient with rT0N3M0 tonsil cancer had local recurrence 5 months after surgery. The 2-year overall survival and 2-year disease-free survival were respectively 100.0% and 93.3% in the 15 patients.Conclusion:NACI combined with TORS provides a safe, effective and minimally invasive treatment for patients with locally advanced oropharyngeal squamous cell carcinoma.
